Peter McNamara - 06 Mar 2026 Form 4 Insider Report for Tectonic Therapeutic, Inc. (TECX)

Role
Chief Scientific Officer
Signature
/s/ Daniel Lochner, Attorney-in-Fact
Issuer symbol
TECX
Transactions as of
06 Mar 2026
Net transactions value
-$188,935
Form type
4
Filing time
09 Mar 2026, 18:12:18 UTC
Previous filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McNamara Peter Chief Scientific Officer C/O TECTONIC THERAPEUTIC, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN /s/ Daniel Lochner, Attorney-in-Fact 09 Mar 2026 0002023255

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECX Common Stock Options Exercise +2,500 +4.2% $2.38* 61,332 06 Mar 2026 Direct F1
transaction TECX Common Stock Options Exercise +215 +0.35% $14.71* 61,547 06 Mar 2026 Direct F1
transaction TECX Common Stock Sale $181,410 -6,047 -9.8% $30.00 55,500 06 Mar 2026 Direct F1
transaction TECX Common Stock Sale $7,525 -215 -0.39% $35.00 55,285 06 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECX Employee Stock Option (Right to Buy) Options Exercise -2,500 -7.3% 31,959 06 Mar 2026 Common Stock 2,500 $2.38 Direct F1, F2, F3
transaction TECX Employee Stock Option (Right to Buy) Options Exercise -215 -2.6% $0.000000* 8,045 06 Mar 2026 Common Stock 215 $14.71 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025.
F2 25% of the shares subject to the option vested on June 1, 2022; and the remainder of the shares subject to the option vest in 36 equal monthly installments with the final amount vesting on June 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F3 Received in exchange for a stock option to acquire 71,029 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017962/xslF345X05/form4-06242024_080611.xml
F4 The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.